


CLAIMS

1. The use of a compound of formula I,



5 wherein R¹ and R² each represent H, or together represent a second carbon-carbon bond between the carbon atoms to which they are attached;

when R¹ and R² each represent H, then R³ and R⁴ also represent H;

when R¹ and R² together represent a second carbon-carbon bond between the carbon atoms to which they are attached, then R³ and R⁴ independently represent H or C₁₋₆ alkyl;

Ar represents:

phenyl or naphthyl, which groups are optionally substituted by one or more groups selected from C₁₋₆ alkyl [which may itself be substituted by one or more substituents selected from halo, C₁₋₆ alkoxy, CO₂H, NH₂, NH(C₁₋₆ alkyl) and N(C₁₋₆ alkyl)₂], halo, C₁₋₆ alkoxy, CO₂H, C₁₋₆ alkoxy carbonyl, NO₂, CN, NH₂, NH(C₁₋₆ alkyl), N(C₁₋₆ alkyl)₂, OH and C₁₋₃ alkylene dioxy, or

a 5- or 6-membered heteroaryl ring containing up to 4 heteroatoms selected from N, O and S, which group is optionally substituted by one or more groups selected from C₁₋₆ alkyl [which may itself be substituted by one or more substituents selected from halo, C₁₋₆ alkoxy, CO₂H, NH₂, NH(C₁₋₆ alkyl) and N(C₁₋₆ alkyl)₂], halo, C₁₋₆ alkoxy, CO₂H, C₁₋₆ alkoxy carbonyl, NO₂, CN, NH₂, NH(C₁₋₆ alkyl) and N(C₁₋₆ alkyl)₂;

or a veterinarian acceptable salt thereof;

in the manufacture of a medicament for the treatment or prophylaxis of an endothelin-mediated disorder in a companion animal.

25 2. The use as claimed in claim 1, wherein the companion animal is as a cat, a dog or a horse.

3. The use as claimed in claim 1 or claim 2, wherein the endothelin-mediated disorder is hypertension, congestive heart failure or chronic renal failure.

*Sub
R3
cont.*

4. The use as claimed in any one of the preceding claims, wherein R¹ and R² each represent H.

5. The use as claimed in any one of the preceding claims, wherein R³ and R⁴ each represent H.

5 6. The use as claimed in any one of the preceding claims, wherein Ar represents phenyl, naphthyl or thienyl, which groups are optionally substituted by one or more groups selected from C₁₋₆ alkyl, halo, CF₃, C₁₋₆ alkoxy, CO₂H and C₁₋₆ alkoxy carbonyl;

7. The use as claimed in any one of the preceding claims, wherein Ar is phenyl.

8. The use as claimed in any one of the preceding claims, wherein the use is for 10 manufacturing a medicament for the treatment of congestive heart failure in a dog.

9. The use as claimed in any one of claims 1 to 7, wherein the use is for manufacturing a medicament for the treatment of chronic renal failure in a cat.

10. A formulation containing a compound of formula I, as defined in claim 1, or a 15 veterinarian acceptable salt thereof, characterized in that it is adapted for administration to a companion animal.

11. A formulation as claimed in claim 10, which is adapted for oral administration and has a taste attractive to the companion animal.

12. A method of treatment or prophylaxis of an endothelin-mediated disorder in a 20 companion animal, which comprises administering an effective amount of a compound of formula I, as defined in claim 1, or a veterinarian acceptable salt thereof, to the companion animal.

13. A pharmaceutical pack comprising a formulation according to claim 10 or 11 and instructions describing the treatment of congestive heart failure in a dog.

14. A pharmaceutical pack comprising a formulation according to claim 10 or 11 25 and instructions describing the treatment of chronic renal failure in a cat.

*ins
R4*